Sculptra^®-Related Complication in Tear-Trough Treatment-A Case Report

背景：舒顏萃是一種聚左旋乳酸產品。自西元1990年於歐洲上市後獲得廣泛地採用，並於西元2004年8月通過美國食品及藥物管理局許可，使用於人類後天免疫缺乏症候群病人之臉部脂肪萎縮。這種刺激型填充劑在台灣應用於臉部美容醫學方面。一位三十歲女性兩年前曾接受過淚溝部位的舒顏萃注射，抱怨兩側的注射部位有結節產生，而且有眼瞼外翻的現象。我們取出了填充劑並討論它造成的影響。材料及方法：一位三十歲女性於兩年前曾接受過淚溝部位的舒顏萃注射，但是結節產生非常明顯。我們呈現處理方式跟討論它產生的併發症。結果：我們使用結膜內開式開刀法在全身麻醉之下進行了手術移除填充物，並將取出之外來物送病理化驗。結論：舒顏萃廣泛應用於臉部脂肪萎縮，但如果應用於眼眶周圍注射的話需要非常的小心，因為併發症可能很明顯。手術移除應是處理此併發症的最後手段但是也是最有效的處理方式。

關鍵字

無資料

並列摘要

Background: Sculptra^®, a product of poly-L-lactic acid, has been used widely in Europe since 1999, and gained U.S. Food and Drug Administration approval for use in human immunodeficiency virus-related facial lipoatrophy in August 2004. This stimulatory filler was then developed for use in other types of facial-filler procedures in Taiwan. A 30-year-old woman who received Sculptra^® injection for depressed tear-trough grooves complained of both nodular formation and ectropion for two years. We removed the filler, and here we discussed its effect. Materials and Methods: A 30-year-old woman received Sculptra^® injection for 2 years, but nodule formation was prominent. We discuss the management of and complications associated with this filler. Results: Surgery for removal of the filler was performed under general anesthesia. A transconjunctival approach was used to remove foreign bodies, and pathological analysis was achieved. The patient was satisfied with the final outcome. Conclusion: Sculptra^® is widely used for facial lipodystropy. Physicians should focus closely on periorbital injection because complications will be troublesome and disturbing. Surgery should be the ultimate but effective method for management.

並列關鍵字

sculptra ； sculptra complication ； poly-1-lactic acid complication ； periorbital injection complication

國際替代計量

全文下載

主題瀏覽